Skip to main content

Articles

Page 16 of 16

  1. In families with high risk of hereditary breast/ovarian cancer (HBOC), women before age 30 do not yet undergo clinical screening, but they are exposed to contradictory information from diverse sources. They ma...

    Authors: Fabrice Kwiatkowski, Mathilde Gay-Bellile, Pascal Dessenne, Claire Laquet, Véronique Boussion, Marie Béguinot, Marie-Françoise Petit, Anne-Sophie Grémeau, Céline Verlet, Charlotte Chaptal, Marilyn Broult, Sylvie Jouvency, Martine Duclos and Yves-Jean Bignon
    Citation: Hereditary Cancer in Clinical Practice 2019 17:7
    Content type: Research Published on:

  2. The current guidelines in Sweden regarding individuals with a clinically actionable (i.e. pathogenic or likely pathogenic) germline TP53 variant recommend patients to take part of the national Swedish P53 Study (...

    Authors: Meis Omran, Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner, Anne Kinhult Ståhlbom, Emma Tham and Svetlana Bajalica-Lagercrantz
    Citation: Hereditary Cancer in Clinical Practice 2020 18:1
    Content type: Research Published on:

  3. Women carrying BRCA-mutations are facing significant challenges, including decision making regarding surveillance and risk-reducing surgery. They often report that they are left alone with these important decisio...

    Authors: Wenche Listøl, Hildegunn Høberg-Vetti, Geir Egil Eide and Cathrine Bjorvatn
    Citation: Hereditary Cancer in Clinical Practice 2017 15:2
    Content type: Research Published on:

  4. Founder mutations in the two breast cancer genes, BRCA1 and BRCA2, have been described in many populations, among these are Ashkenazi-Jewish, Polish, Norwegian and Icelandic. Founder mutation testing in patients ...

    Authors: Cecilie Heramb, Teresia Wangensteen, Eli Marie Grindedal, Sarah Louise Ariansen, Sheba Lothe, Ketil Riddervold Heimdal and Lovise Mæhle
    Citation: Hereditary Cancer in Clinical Practice 2018 16:3
    Content type: Research Published on:

  5. Patients with a genetic variant associated with Lynch syndrome (LS) are recommended to undergo frequent and repeated cancer surveillance activities to minimize cancer-related morbidity and mortality. Little is...

    Authors: Jennifer L. Schneider, Katrina A. B. Goddard, Kristin R. Muessig, James V. Davis, Alan F. Rope, Jessica E. Hunter, Susan K. Peterson, Louise S. Acheson, Sapna Syngal, Georgia L. Wiesner and Jacob A. Reiss
    Citation: Hereditary Cancer in Clinical Practice 2018 16:11
    Content type: Research Published on:

  6. First-degree relatives (FDRs) of probands with colorectal cancer (CRC) may be at increased risk of CRC and require colonoscopy. Proband disclosure about this risk and need for colonoscopy is essential for FDRs...

    Authors: Kaitlin M. McGarragle, Crystal Hare, Spring Holter, Dorian Anglin Facey, Kelly McShane, Steven Gallinger and Tae L. Hart
    Citation: Hereditary Cancer in Clinical Practice 2019 17:16
    Content type: Research Published on:

  7. Endometrial, ovarian and breast cancers are paradigms for global health disparity. Women living in the developing world continue to present in later stages of disease and have fewer options for treatment than ...

    Authors: Hanoon P. Pokharel, Neville F. Hacker and Lesley Andrews
    Citation: Hereditary Cancer in Clinical Practice 2017 15:12
    Content type: Research Published on:

  8. In kindreds carrying path_BRCA1/2 variants, some women in these families will develop cancer despite testing negative for the family’s pathogenic variant. These families may have additional genetic variants, whic...

    Authors: Mev Dominguez-Valentin, D. Gareth R. Evans, Sigve Nakken, Hélène Tubeuf, Daniel Vodak, Per Olaf Ekstrøm, Anke M. Nissen, Monika Morak, Elke Holinski-Feder, Alexandra Martins, Pål Møller and Eivind Hovig
    Citation: Hereditary Cancer in Clinical Practice 2018 16:4
    Content type: Research Published on:

  9. Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for the development of breast and/or ovarian cancer. The frequency and spectrum of mutations in these genes has not yet been exam...

    Authors: P. Wojcik, M. Jasiowka, E. Strycharz, M. Sobol, D. Hodorowicz-Zaniewska, P. Skotnicki, T. Byrski, P. Blecharz, E. Marczyk, I. Cedrych, J. Jakubowicz, J. Lubiński, V. Sopik, S. Narod and P. Pierzchalski
    Citation: Hereditary Cancer in Clinical Practice 2016 14:5
    Content type: Research Published on:

  10. Pancreatic cancer (PC) is an aggressive disease with a dismal 5-year survival rate. Surveillance of high-risk individuals is hoped to improve survival outcomes by detection of precursor lesions or early-stage ...

    Authors: Tanya Dwarte, Skye McKay, Amber Johns, Katherine Tucker, Allan D. Spigelman, David Williams and Alina Stoita
    Citation: Hereditary Cancer in Clinical Practice 2019 17:30
    Content type: Research Published on:

  11. Pancreatic cancer is a very aggressive disease with a poor prognosis. The majority of them are attributed to sporadic causes, especially to many modifiable risk factors such as tobacco or alcohol abuse. The pr...

    Authors: Sergio Carrera, Aintzane Sancho, Eider Azkona, Josune Azkuna and Guillermo Lopez-Vivanco
    Citation: Hereditary Cancer in Clinical Practice 2017 15:9
    Content type: Review Published on:

  12. Breast cancer (BC) is an important public health problem worldwide. In Brazil, breast cancer is the most frequently diagnosed tumor and the leading cause of cancer death in women. Hereditary cancer represents ...

    Authors: Gabriela C. Fernandes, Rodrigo A. D. Michelli, Cristovam Scapulatempo-Neto and Edenir I. Palmero
    Citation: Hereditary Cancer in Clinical Practice 2016 14:2
    Content type: Research Published on:

  13. The main risk factor for familial breast cancer is the presence of mutations in BRCA1 and BRCA2 genes. The prevalence of mutations in these genes is heterogeneous and varies according to geographical origin of...

    Authors: Carolina Cortés, Ana Lucía Rivera, David Trochez, Melissa Solarte, Daniela Gómez, Laura Cifuentes and Guillermo Barreto
    Citation: Hereditary Cancer in Clinical Practice 2019 17:20
    Content type: Research Published on:

  14. BRCA phenocopies are individuals with the same phenotype (i.e. cancer consistent with Hereditary Breast and Ovarian Cancer syndrome = HBOC) as their affected relatives, but not the same genotype as assessed by bl...

    Authors: Lela Buckingham, Rachel Mitchell, Mark Maienschein-Cline, Stefan Green, Vincent Hong Hu, Melody Cobleigh, Jacob Rotmensch, Kelly Burgess and Lydia Usha
    Citation: Hereditary Cancer in Clinical Practice 2019 17:21
    Content type: Research Published on:

  15. The number of individuals meeting criteria for genetic counseling and testing for hereditary cancer syndromes (HCS) is far less than the number that actually receive it. To facilitate identification of patient...

    Authors: Leslie Bucheit, Katherine Johansen Taber and Kaylene Ready
    Citation: Hereditary Cancer in Clinical Practice 2019 17:2
    Content type: Research Published on:

  17. Hereditary cancer predisposition syndromes comprise approximately 10% of diagnosed cancers; however, familial forms are believed to account for up to 30% of some cancers. In Hispanics, the most commonly diagno...

    Authors: Marcia Cruz-Correa, Julyann Pérez-Mayoral, Julie Dutil, Miguel Echenique, Rafael Mosquera, Keila Rivera-Román, Sharee Umpierre, Segundo Rodriguez-Quilichini, Maria Gonzalez-Pons, Myrta I. Olivera and Sherly Pardo
    Citation: Hereditary Cancer in Clinical Practice 2017 15:3
    Content type: Review Published on:

  18. Extensive clinical and genetic heterogeneity of inherited cancers has allowed multi-gene panel testing to become an efficient means for identification of patients with an inherited predisposition to a broad sp...

    Authors: Sabrina A. Gardner, Katelyn S. Weymouth, Wei S. Kelly, Ekaterina Bogdanova, Wenjie Chen, Daniel Lupu, Joshua Suhl, Qiandong Zeng, Ute Geigenmüller, Debbie Boles, Patricia M. Okamoto, Geraldine McDowell, Melissa A. Hayden and Narasimhan Nagan
    Citation: Hereditary Cancer in Clinical Practice 2018 16:1
    Content type: Research Published on:

  19. Triple negative breast cancers (TNBC) are associated with an aggressive clinical course, earlier recurrence and short survival. BRCA – mutated tumours represent up to 25% of all TNBC. BRCA status is being studied...

    Authors: Olga Caramelo, Cristina Silva, Francisco Caramelo, Cristina Frutuoso and Teresa Almeida-Santos
    Citation: Hereditary Cancer in Clinical Practice 2019 17:11
    Content type: Review Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    1.7 - 2-year Impact Factor
    2.2 - 5-year Impact Factor
    0.634 - SNIP (Source Normalized Impact per Paper)
    0.526 - SJR (SCImago Journal Rank)

    2023 Speed
    13 days submission to first editorial decision for all manuscripts (Median)
    131 days submission to accept (Median)

    2023 Usage 
    394,813 downloads
    196 Altmetric mentions

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287